LAKE FOREST, Ill., March 4, 2014 /PRNewswire/ -- Hospira, Inc. (NYSE: HSP), the world's leading provider of injectable drugs and infusion technologies, today announced that David J. Endicott has been named President, Hospira Medical Devices, effective March 10, 2014. In this newly created role, Mr. Endicott will have responsibility for establishing a fully integrated device organization leading the commercial, research and development, manufacturing and related support functions to continue to advance the company's product pipeline, execute its device strategy and ultimately drive global growth. He will serve as a member of Hospira's senior leadership team and report directly to F. Michael Ball, chief executive officer.
"Given the growing focus in healthcare on improving patient safety and clinical outcomes, we see our device business as a strategic growth driver for Hospira," said Mr. Ball. "David brings the perfect blend of vision and experience to lead our efforts, and his appointment will establish executive leadership for this $1 billion business." Added Mr. Ball, "David is an accomplished global leader with more than 25 years of industry experience 15+ of those where I had the privilege of working with him directly and had an opportunity to see firsthand his proven ability to define, implement and manage sustainable process, organizational and cultural change. With his impressive track record in delivering strong results across all business functions, we're confident David will successfully lead our dual imperatives to execute our device strategy and drive global growth."
Mr. Endicott, 49, most recently served as President, Allergan Medical, Asia Pacific and Latin America and as an executive committee member of Allergan, Inc., a global specialty drug and medical device company. Prior to this position, he served as President, Europe, Africa and Middle East. During his tenure at Allergan, he held roles of progressive responsibility across a variety of functions, driving rapid growth in global markets, developing deep operating experience and demonstrating great success in building integrated, high-performing teams.
Mr. Endicott earned his bachelor's degree in chemistry from Whitman College, his master's in business administration from the University of Southern California and is a graduate of the Harvard Business School Advanced Management Program.
Hospira, Inc. is the world's leading provider of injectable drugs and infusion technologies, and a global leader in biosimilars. Through its broad, integrated portfolio, Hospira is uniquely positioned to Advance Wellness by improving patient and caregiver safety while reducing healthcare costs. The company is headquartered in Lake Forest, Ill., and has approximately 17,000 employees. Learn more at www.hospira.com.
Photo - http://photos.prnewswire.com/prnh/20140303/CG75886
SOURCE Hospira, Inc.